Novel Advances in Assay Development and Screening Technologies to Improve Lead Discovery and Increase In Vivo Translation and Reduce Attrition in Small Molecule Drug Discovery.
Drug Discovery Innovations 2015- Cell Based Assays, Phenotypic Screening and Pioneering Technologies will provide you with the latest leading-edge strategies being pursued to improve target identification and validation in early stage drug discovery and to improve R&D efficiency. The 2015 programme will address issues, breakthroughs and developments to improve your day to day role, identifying better quality candidate drugs to increase translation to clinical results.
2015 Programme Highlights:
Sourcing and Designing More Physiologically Relevant Cellular Assays for Implementation in HTS Programmes
Overcoming Patient Variability
Application of Genome Editing
Practical Strategies for Developing 3D Cell Culture Assays for Use in Drug Discovery
Phenotypic Screening and Complex Disease Assays
Target Deconvolution Strategies in Phenotypic Screening
Image Analysis and Data Collection, Storage and Interpretation
Open-Access Collaboration in Accelerating Early Novel advances in assay development and screening technologies to improve lead discovery and increase correlation to in vivo and clinical results.
13 Industry Case Studies:
Benchmark your screening strategies against leading industry figures including GSK, Novartis, Roche, Pfizer, Janssen and Actelion
- Present your latest scientific developments or launch new technology products on the conference programme to the sectors most important decision-makers
- Build brand awareness amongst industry’s best through an exhibition stand and extensive marketing opportunities that guarantee you achieve high visibility
- Increased activities to encourage interaction between speakers, delegates and exhibitors including strategic round table discussions, panels, debates
Please see website: 00
Speakers: Steve Ludbrook, Group Leader Biological Sciences GlaxoSmithKline R&D, UK, Ulrich Schopfer, Executive Director, Head Integrated Lead Discovery, Novartis Institutes for BioMedical Research, Switzerland, Laure Bouchez, Senior Principal Scientist, Novartis Institutes for Biomedical Research, Switzerland, Michael Hennig Head of Global Discovery Technologies F. Hoffmann - La Roche Ltd., Marco Prunotto Phenotypic Drug Discovery & Target Identification Lead Roche, Yolanda T. Chong, Principal Scientist, Janssen Pharmaceutica, Belgium, Niclas Nilsson Open Innovation Manager, LEO Pharma, Denmark, Magda Bictash, Senior Principal Scientist, Neusentis (A Pfizer Research Unit), UK, Xavier Leroy, Project Promoter & Leader, Actelion Pharmaceuticals Ltd, Switzerland, Jeffrey Beekman, Associate Professor, UMC Utrecht, The Netherlands, Peter Horvath Finnish Distinguished Professor, FIMM Helsinki, Finland; Hungarian Academy of Sciences, Hungary